Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines

Journal of Proteome Research

Volumn 12, Issue 4, 2013, Pages 1898-1908

  Van De Waterbeemd, Bas ^a   Mommen, Geert P M ^a,b,c   Pennings, Jeroen L A ^d   Eppink, Michel H ^e   Wijffels, René H ^e   Van Der Pol, Leo A ^a   De Jong, Ad P J M ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

common reference; immunogenicity; N proteomics; OMV; outer membrane vesicles; PTAG; quantitative proteomics; vaccine

Indexed keywords

CYTOPLASM PROTEIN; ENDOTOXIN; OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; DETERGENT EXTRACTION; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SYNTHESIS;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CYTOPLASM; DETERGENTS; FEMALE; LIPOPROTEINS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEOMICS;

NEISSERIA MENINGITIDIS SEROGROUP B; OAT MOSAIC VIRUS;

EID: 84875923227     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr301208g     Document Type: Article

References (73)

1. Girard, M. P.; Preziosi, M. P.; Aguado, M. T.; Kieny, M. P. A review of vaccine research and development: meningococcal disease Vaccine 2006, 24 (22) 4692-700
2. Jodar, L.; Feavers, I. M.; Salisbury, D.; Granoff, D. M. Development of vaccines against meningococcal disease Lancet 2002, 359 (9316) 1499-508
3. Bjune, G.; Hoiby, E. A.; Gronnesby, J. K.; Arnesen, O.; Fredriksen, J. H.; Halstensen, A.; Holten, E.; Lindbak, A. K.; Nokleby, H.; Rosenqvist, E. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway Lancet 1991, 338 (8775) 1093-6
4. Sierra, G. V.; Campa, H. C.; Varcacel, N. M.; Garcia, I. L.; Izquierdo, P. L.; Sotolongo, P. F.; Casanueva, G. V.; Rico, C. O.; Rodriguez, C. R.; Terry, M. H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann. 1991, 14 (2) 195-207
5. 208-10.
6. Thornton, V.; Lennon, D.; Rasanathan, K.; O'Hallahan, J.; Oster, P.; Stewart, J.; Tilman, S.; Aaberge, I.; Feiring, B.; Nokleby, H.; Rosenqvist, E.; White, K.; Reid, S.; Mulholland, K.; Wakefield, M. J.; Martin, D. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control Vaccine 2006, 24 (9) 1395-400
7. Ellis, T. N.; Kuehn, M. J. Virulence and immunomodulatory roles of bacterial outer membrane vesicles Microbiol. Mol. Biol. Rev. 2010, 74 (1) 81-94
8. Deatherage, B. L.; Lara, J. C.; Bergsbaken, T.; Barrett, S. L.; Lara, S.; Cookson, B. T. Biogenesis of Bacterial Membrane Vesicles. Mol. Microbiol. 2009, not supplied.
9. van der Ley, P.; Heckels, J. E.; Virji, M.; Hoogerhout, P.; Poolman, J. T. Topology of outer membrane porins in pathogenic Neisseria spp Infect. Immun. 1991, 59 (9) 2963-71
10. Martin, D. R.; Ruijne, N.; McCallum, L.; O'Hallahan, J.; Oster, P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB Clin. Vaccine Immunol. 2006, 13 (4) 486-91
11. van der Ley, P.; van der Biezen, J.; Poolman, J. T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine Vaccine 1995, 13 (4) 401-7
12. van den Dobbelsteen, G. P.; van Dijken, H. H.; Pillai, S.; van Alphen, L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs Vaccine 2007, 25 (13) 2491-6
13. Zollinger, W. D.; Donets, M. A.; Schmiel, D. H.; Pinto, V. B.; Labrie, J.; Moran, E. E.; Brandt, B. L.; Ionin, B.; Marques, R.; Wu, M.; Chen, P.; Stoddard, M. B.; Keiser, P. B. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine Vaccine 2010, 28 (31) 5057-67
14. Urwin, R.; Russell, J. E.; Thompson, E. A.; Holmes, E. C.; Feavers, I. M.; Maiden, M. C. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design Infect. Immun. 2004, 72 (10) 5955-62
15. Zollinger, W. D.; Poolman, J. T.; Maiden, M. C. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev. Vaccines 2011, 10 (5) 559-61
16. Wheeler, J. X.; Vipond, C.; Feavers, I. M. Exploring the proteome of meningococcal outer membrane vesicle vaccines Proteomics Clin. Appl. 2007, 1 (9) 1198-210
17. Claassen, I.; Meylis, J.; van der Ley, P.; Peeters, C.; Brons, H.; Robert, J.; Borsboom, D.; van der Ark, A.; van Straaten, I.; Roholl, P.; Kuipers, B.; Poolman, J. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine Vaccine 1996, 14 (10) 1001-8
18. Fredriksen, J. H.; Rosenqvist, E.; Wedege, E.; Bryn, K.; Bjune, G.; Froholm, L. O.; Lindbak, A. K.; Mogster, B.; Namork, E.; Rye, U.; Stabbetorp, G.; Winsnes, R.; Aase, B.; Closs, O. Production, characterization and control of MenB-vaccine ″Folkehelsa″: an outer membrane vesicle vaccine against group B meningococcal disease NIPH Ann. 1991, 14 (2) 67-79 discussion 79-80.
19. de Moraes, J. C.; Perkins, B. A.; Camargo, M. C.; Hidalgo, N. T.; Barbosa, H. A.; Sacchi, C. T.; Landgraf, I. M.; Gattas, V. L.; Vasconcelos Hde, G. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil Lancet 1992, 340 (8827) 1074-8
20. Boslego, J.; Garcia, J.; Cruz, C.; Zollinger, W.; Brandt, B.; Ruiz, S.; Martinez, M.; Arthur, J.; Underwood, P.; Silva, W. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease Vaccine 1995, 13 (9) 821-9
21. van de Waterbeemd, B.; Streefland, M.; van der Ley, P.; Zomer, B.; van Dijken, H.; Martens, D.; Wijffels, R.; van der Pol, L. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process Vaccine 2010, 28 (30) 4810-6
22. van der Ley, P.; Steeghs, L.; Hamstra, H. J.; ten Hove, J.; Zomer, B.; van Alphen, L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity Infect. Immun. 2001, 69 (10) 5981-90
23. van der Ley, P.; van den Dobbelsteen, G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants Hum. Vaccin. 2011, 7 (8) 886-90
24. van de Waterbeemd, B.; Streefland, M.; van Keulen, L.; van den IJssel, J.; de Haan, A.; Eppink, M. H.; van der Pol, L. A. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis Vaccine 2012, 30 (24) 3683-90
25. Keiser, P. B.; Biggs-Cicatelli, S.; Moran, E. E.; Schmiel, D. H.; Pinto, V. B.; Burden, R. E.; Miller, L. B.; Moon, J. E.; Bowden, R. A.; Cummings, J. F.; Zollinger, W. D. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression Vaccine 2010, 29 (7) 1413-20
26. Pinto, V. B.; Moran, E. E.; Cruz, F.; Wang, X. M.; Fridman, A.; Zollinger, W. D.; Przysiecki, C. T.; Burden, R. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups Vaccine 2011, 29 (44) 7752-8
27. Prachayasittikul, V.; Isarankura-Na-Ayudhya, C.; Tantimongcolwat, T.; Nantasenamat, C.; Galla, H. J. EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes Acta Biochim. Biophys. Sin. (Shanghai) 2007, 39 (11) 901-13
28. Haque, H.; Russell, A. D. Effect of chelating agents on the susceptibility of some strains of gram-negative bacteria to some antibacterial agents Antimicrob. Agents Chemother. 1974, 6 (2) 200-6
29. Post, D. M.; Zhang, D.; Eastvold, J. S.; Teghanemt, A.; Gibson, B. W.; Weiss, J. P. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B J. Biol. Chem. 2005, 280 (46) 38383-94
30. Koeberling, O.; Seubert, A.; Granoff, D. M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin J. Infect. Dis. 2008, 198 (2) 262-70
31. Koeberling, O.; Seubert, A.; Santos, G.; Colaprico, A.; Ugozzoli, M.; Donnelly, J.; Granoff, D. M. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys Vaccine 2011, 29 (29-30) 4728-34
32. Ferrari, G.; Garaguso, I.; Adu-Bobie, J.; Doro, F.; Taddei, A. R.; Biolchi, A.; Brunelli, B.; Giuliani, M. M.; Pizza, M.; Norais, N.; Grandi, G. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles Proteomics 2006, 6 (6) 1856-66
33. Koeberling, O.; Delany, I.; Granoff, D. M. A critical threshold of meningococcal factor h binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines Clin. Vaccine Immunol. 2011, 18 (5) 736-42
34. Borrow, R.; Balmer, P.; Miller, E. Meningococcal surrogates of protection - serum bactericidal antibody activity Vaccine 2005, 23 (17-18) 2222-7
35. Holst, J.; Feiring, B.; Fuglesang, J. E.; Hoiby, E. A.; Nokleby, H.; Aaberge, I. S.; Rosenqvist, E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease Vaccine 2003, 21 (7-8) 734-7
36. Vipond, C.; Suker, J.; Jones, C.; Tang, C.; Feavers, I. M.; Wheeler, J. X. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254 Proteomics 2006, 6 (11) 3400-13
37. Vipond, C.; Wheeler, J. X.; Jones, C.; Feavers, I. M.; Suker, J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry Hum. Vaccin. 2005, 1 (2) 80-4
38. Williams, J. N.; Skipp, P. J.; Humphries, H. E.; Christodoulides, M.; O'Connor, C. D.; Heckels, J. E. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant Infect. Immun. 2007, 75 (3) 1364-72
39. Tsolakos, N.; Lie, K.; Bolstad, K.; Maslen, S.; Kristiansen, P. A.; Hoiby, E. A.; Wallington, A.; Vipond, C.; Skehel, M.; Tang, C. M.; Feavers, I. M.; Wedege, E.; Wheeler, J. X. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media Vaccine 2010, 28 (18) 3211-8
40. Gil, J.; Betancourt, L. H.; Sardinas, G.; Yero, D.; Niebla, O.; Delgado, M.; Garcia, D.; Pajon, R.; Sanchez, A.; Gonzalez, L. J.; Padron, G.; Campa, C.; Sotolongo, F.; Barbera, R.; Guillen, G.; Herrera, L.; Besada, V. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: A road map for discovery new antigens Hum. Vaccin. 2009, 5 (5) 347-56
41. Gevaert, K.; Van Damme, P.; Ghesquiere, B.; Impens, F.; Martens, L.; Helsens, K.; Vandekerckhove, J. A la carte proteomics with an emphasis on gel-free techniques Proteomics 2007, 7 (16) 2698-718
42. Boersema, P. J.; Raijmakers, R.; Lemeer, S.; Mohammed, S.; Heck, A. J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics Nat. Protoc. 2009, 4 (4) 484-94
43. Bantscheff, M.; Schirle, M.; Sweetman, G.; Rick, J.; Kuster, B. Quantitative mass spectrometry in proteomics: a critical review Anal. Bioanal. Chem. 2007, 389 (4) 1017-31
44. Cox, J.; Mann, M. Quantitative, high-resolution proteomics for data-driven systems biology Annu. Rev. Biochem. 2011, 80, 273-99
45. Boersema, P. J.; Aye, T. T.; van Veen, T. A.; Heck, A. J.; Mohammed, S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates Proteomics 2008, 8 (22) 4624-32
46. Gevaert, K.; Goethals, M.; Martens, L.; Van Damme, J.; Staes, A.; Thomas, G. R.; Vandekerckhove, J. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides Nat. Biotechnol. 2003, 21 (5) 566-9
47. McDonald, L.; Beynon, R. J. Positional proteomics: preparation of amino-terminal peptides as a strategy for proteome simplification and characterization Nat. Protoc. 2006, 1 (4) 1790-8
48. McDonald, L.; Robertson, D. H.; Hurst, J. L.; Beynon, R. J. Positional proteomics: selective recovery and analysis of N-terminal proteolytic peptides Nat. Methods 2005, 2 (12) 955-7
49. Kleifeld, O.; Doucet, A.; auf dem Keller, U.; Prudova, A.; Schilling, O.; Kainthan, R. K.; Starr, A. E.; Foster, L. J.; Kizhakkedathu, J. N.; Overall, C. M. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products Nat. Biotechnol. 2010, 28 (3) 281-8
50. Guryca, V.; Lamerz, J.; Ducret, A.; Cutler, P. Qualitative improvement and quantitative assessment of N-terminomics Proteomics 2012, 12 (8) 1207-16
51. Wildes, D.; Wells, J. A. Sampling the N-terminal proteome of human blood Proc. Natl. Acad. Sci. U.S.A. 2010, 107 (10) 4561-6
52. Mommen, G. P.; van de Waterbeemd, B.; Meiring, H. D.; Kersten, G.; Heck, A. J.; de Jong, A. P. Unbiased Selective Isolation of Protein N-terminal Peptides from Complex Proteome Samples Using Phospho Tagging (PTAG) and TiO2-based Depletion Mol. Cell. Proteomics 2012, 11 (9) 832-42
53. Holten, E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978 J. Clin. Microbiol. 1979, 9 (2) 186-8
54. Baart, G. J.; de Jong, G.; Philippi, M.; Van't Riet, K.; van der Pol, L. A.; Beuvery, E. C.; Tramper, J.; Martens, D. E. Scale-up for bulk production of vaccine against meningococcal disease Vaccine 2007, 25 (34) 6399-408
55. Baart, G. J.; Willemsen, M.; Khatami, E.; de Haan, A.; Zomer, B.; Beuvery, E. C.; Tramper, J.; Martens, D. E. Modeling Neisseria meningitidis B metabolism at different specific growth rates Biotechnol. Bioeng. 2008, 101 (5) 1022-35
56. Smith, R. D.; Anderson, G. A.; Lipton, M. S.; Pasa-Tolic, L.; Shen, Y.; Conrads, T. P.; Veenstra, T. D.; Udseth, H. R. An accurate mass tag strategy for quantitative and high-throughput proteome measurements Proteomics 2002, 2 (5) 513-23
57. Conrads, T. P.; Anderson, G. A.; Veenstra, T. D.; Pasa-Tolic, L.; Smith, R. D. Utility of accurate mass tags for proteome-wide protein identification Anal. Chem. 2000, 72 (14) 3349-54
58. Meiring, H. D.; van der Heeft, E.; ten Hove, G. J.; de Jong, A. P. J. M. Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis J. Sep. Sci. 2002, 25 (9) 557-68
59. Cappadona, S.; Baker, P. R.; Cutillas, P. R.; Heck, A. J.; van Breukelen, B. Current challenges in software solutions for mass spectrometry-based quantitative proteomics Amino Acids 2012, 43 (3) 1087-108
60. Yu, N. Y.; Wagner, J. R.; Laird, M. R.; Melli, G.; Rey, S.; Lo, R.; Dao, P.; Sahinalp, S. C.; Ester, M.; Foster, L. J.; Brinkman, F. S. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes Bioinformatics 2010, 26 (13) 1608-15
61. Luque-Garcia, J. L.; Zhou, G.; Spellman, D. S.; Sun, T. T.; Neubert, T. A. Analysis of electroblotted proteins by mass spectrometry: protein identification after Western blotting Mol. Cell. Proteomics 2008, 7 (2) 308-14
62. Petersen, T. N.; Brunak, S.; von Heijne, G.; Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions Nat. Methods 2011, 8 (10) 785-6
63. Kovacs-Simon, A.; Titball, R. W.; Michell, S. L. Lipoproteins of bacterial pathogens Infect. Immun. 2010, 79 (2) 548-61
64. Tsai, C. M.; Frasch, C. E.; Mocca, L. F. Five structural classes of major outer membrane proteins in Neisseria meningitidis J. Bacteriol. 1981, 146 (1) 69-78
65. Frasch, C. E. Vaccines for prevention of meningococcal disease Clin. Microbiol. Rev. 1989, 2 (Suppl) S134-8
66. van Ulsen, P.; Kuhn, K.; Prinz, T.; Legner, H.; Schmid, P.; Baumann, C.; Tommassen, J. Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach Proteomics 2009, 9 (7) 1771-81
67. Grifantini, R.; Sebastian, S.; Frigimelica, E.; Draghi, M.; Bartolini, E.; Muzzi, A.; Rappuoli, R.; Grandi, G.; Genco, C. A. Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (16) 9542-7
68. Kulp, A.; Kuehn, M. J. Biological functions and biogenesis of secreted bacterial Outer Membrane Vesicles Annu. Rev. Microbiol. 2010, 64, 163-84
69. Andreev, V. P.; Petyuk, V. A.; Brewer, H. M.; Karpievitch, Y. V.; Xie, F.; Clarke, J.; Camp, D.; Smith, R. D.; Lieberman, A. P.; Albin, R. L.; Nawaz, Z.; El Hokayem, J.; Myers, A. J. Label-free quantitative LC-MS proteomics of Alzheimer's Disease and normally aged human brains J. Proteome Res. 2012, 11 (6) 3053-67
70. Jiang, H. Q.; Hoiseth, S. K.; Harris, S. L.; McNeil, L. K.; Zhu, D.; Tan, C.; Scott, A. A.; Alexander, K.; Mason, K.; Miller, L.; DaSilva, I.; Mack, M.; Zhao, X. J.; Pride, M. W.; Andrew, L.; Murphy, E.; Hagen, M.; French, R.; Arora, A.; Jones, T. R.; Jansen, K. U.; Zlotnick, G. W.; Anderson, A. S. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease Vaccine 2010, 28 (37) 6086-93
71. Snape, M. D.; Dawson, T.; Oster, P.; Evans, A.; John, T. M.; Ohene-Kena, B.; Findlow, J.; Yu, L. M.; Borrow, R.; Ypma, E.; Toneatto, D.; Pollard, A. J. Immunogenicity of 2 investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial Pediatr. Infect. Dis. J. 2010, 29 (11) ee71-9
72. Arigita, C.; Kersten, G. F.; Hazendonk, T.; Hennink, W. E.; Crommelin, D. J.; Jiskoot, W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes Vaccine 2003, 21 (9-10) 950-60
73. Steeghs, L.; Tommassen, J.; Leusen, J. H.; van de Winkel, J. G.; van der Ley, P. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development J. Endotoxin Res. 2004, 10 (2) 113-9